Literature DB >> 7747814

Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.

N A Gruis1, J Weaver-Feldhaus, Q Liu, C Frye, R Eeles, I Orlow, L Lacombe, V Ponce-Castaneda, P Lianes, E Latres.   

Abstract

The 9p21 region of human chromosome 9 is a hot spot for chromosomal aberrations in both cultured cell lines and primary tumors. This region contains a gene, P16 (also called MTS1, CDKN2 and p16INK4), that encodes a presumptive negative cell cycle regulator called p16. P16 is deleted or mutated at high frequency in a variety of tumor cell lines including melanoma and bladder carcinoma lines. As such, it is likely to be a tumor suppressor gene. Here we show that P16 is mutated in primary bladder carcinomas (3 of 33) and melanomas (5 of 34). These findings support studies that show P16 mutations are not solely a product of growth in tissue culture but rather are involved in formation of tumors in viva. Some bladder primary tumors and some bladder and melanoma tumor cell lines contain mutations in both P16 and P53 at frequencies that suggest that p53 and p16 function in different pathways, each of which is important in suppressing malignant transformation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7747814      PMCID: PMC1869278     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  24 in total

1.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

2.  p53 sweeps through cancer research.

Authors:  E Culotta; D E Koshland
Journal:  Science       Date:  1993-12-24       Impact factor: 47.728

3.  Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma.

Authors:  J S Castresana; M P Rubio; J J Vázquez; M Idoate; A J Sober; B R Seizinger; R L Barnhill
Journal:  Int J Cancer       Date:  1993-10-21       Impact factor: 7.396

4.  Mutations and altered expression of p16INK4 in human cancer.

Authors:  A Okamoto; D J Demetrick; E A Spillare; K Hagiwara; S P Hussain; W P Bennett; K Forrester; B Gerwin; M Serrano; D H Beach
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

5.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.

Authors:  M Serrano; G J Hannon; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

6.  p21 is a universal inhibitor of cyclin kinases.

Authors:  Y Xiong; G J Hannon; H Zhang; D Casso; R Kobayashi; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

7.  Rates of p16 (MTS1) mutations in primary tumors with 9p loss.

Authors:  P Cairns; L Mao; A Merlo; D J Lee; D Schwab; Y Eby; K Tokino; P van der Riet; J E Blaugrund; D Sidransky
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

8.  p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma.

Authors:  J Q Cheng; S C Jhanwar; W M Klein; D W Bell; W C Lee; D A Altomare; T Nobori; O I Olopade; A J Buckler; J R Testa
Journal:  Cancer Res       Date:  1994-11-01       Impact factor: 12.701

9.  Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.

Authors:  C Caldas; S A Hahn; L T da Costa; M S Redston; M Schutte; A B Seymour; C L Weinstein; R H Hruban; C J Yeo; S E Kern
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

10.  Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma.

Authors:  T Mori; K Miura; T Aoki; T Nishihira; S Mori; Y Nakamura
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

View more
  13 in total

Review 1.  Genetics of bladder cancer.

Authors:  K K Saran; D Gould; C J Godec; R S Verma
Journal:  J Mol Med (Berl)       Date:  1996-08       Impact factor: 4.599

2.  Validation of denaturing high performance liquid chromatography as a rapid detection method for the identification of human INK4A gene mutations.

Authors:  I Orlow; P Roy; A Barz; R Canchola; Y Song; M Berwick
Journal:  J Mol Diagn       Date:  2001-11       Impact factor: 5.568

Review 3.  Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer.

Authors:  C Cordon-Cardo; J Sheinfeld
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 4.  Molecular aspects of melanocytic dysplastic nevi.

Authors:  Mahmoud Rezk Abd-Elwahed Hussein; Gary Stewart Wood
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

5.  Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi.

Authors:  T Papp; H Pemsel; R Zimmermann; R Bastrop; D G Weiss; D Schiffmann
Journal:  J Med Genet       Date:  1999-08       Impact factor: 6.318

6.  Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions.

Authors:  T Papp; M Jafari; D Schiffmann
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

7.  Frequent p16-independent inactivation of p14ARF in human melanoma.

Authors:  Daniel E Freedberg; Sushila H Rigas; Julie Russak; Weiming Gai; Margarita Kaplow; Iman Osman; Faye Turner; Juliette A Randerson-Moor; Alan Houghton; Klaus Busam; D Timothy Bishop; Boris C Bastian; Julia A Newton-Bishop; David Polsky
Journal:  J Natl Cancer Inst       Date:  2008-05-27       Impact factor: 13.506

Review 8.  Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia.

Authors:  C Cordon-Cardo
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

9.  Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma.

Authors:  A Platz; U Ringborg; B Lagerlöf; E Lundqvist; P Sevigny; M Inganäs
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

10.  Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases.

Authors:  A Platz; P Sevigny; T Norberg; P Ring; B Lagerlöf; U Ringborg
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.